
DFTX Stock Forecast & Price Target
DFTX Analyst Ratings
Bulls say
Definium Therapeutics is viewed favorably because DT120 has produced three consecutive Phase 3 wins across GAD and MDD, including a 5.1-point placebo-adjusted HAM-A improvement in PANORAMA and an 8.1-point placebo-adjusted MADRS improvement in EMERGE, with a clean safety profile and rapid onset. The company’s Breakthrough Therapy Designation in both indications, plus a scheduled pre-NDA meeting in 4Q26 and NDA filing anticipated in 1H27, strengthens the regulatory path and raises the possibility of a broader dual-indication label. Survey work and updated modeling suggest a combined ~$2.3B opportunity across GAD and MDD, while the stock trading near cash implies the market may be underpricing the commercial upside of a differentiated, single-dose psychiatry franchise.
Bears say
Definium Therapeutics is viewed negatively because its lead DT120 ODT remains exposed to major clinical risk, including the possibility that early anxiety signals are not reproducible and that long-term safety is not well known. The stock also faces meaningful regulatory and commercialization hurdles beyond FDA approval, including DEA rescheduling, REMS requirements, stigma, and slow physician adoption, any of which could limit market access even after the four Phase 3 trials. In addition, the company lacks a composition-of-matter patent for LSD and may have to rely mainly on regulatory exclusivity, while still facing the risk of being unable to fund operations with no commercial products.
This aggregate rating is based on analysts' research of Definium Therapeutics Inc and is not a guaranteed prediction by Public.com or investment advice.
DFTX Analyst Forecast & Price Prediction
Start investing in DFTX
Order type
Buy in
Order amount
Est. shares
0 shares
FAQs About Definium Therapeutics Inc (DFTX) Forecast
DFTX Analyst Forecast & Price Prediction
Start investing in DFTX
Order type
Buy in
Order amount
Est. shares
0 shares